Association between antimicrobial consumption and resistance in Escherichia coif

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 912-917

  Bergman, Miika ^a   Nyberg, Solja T ^a   Huovinen, Pentti ^a   Paakkari, Pirkko ^b   Hakanen, Antti J ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b NATIONAL AGENCY FOR MEDICINES   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFALEXIN; CEFALOTIN; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; LEVOFLOXACIN; MECILLINAM; NITROFURANTOIN; NORFLOXACIN; PIVMECILLINAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG USE; ESCHERICHIA COLI; FINLAND; HUMAN; NONHUMAN; OUTPATIENT; PRIORITY JOURNAL; URINALYSIS;

AMBULATORY CARE FACILITIES; AMDINOCILLIN PIVOXIL; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; AMPICILLIN; ANTI-INFECTIVE AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FINLAND; FLUOROQUINOLONES; HOSPITALS, COMMUNITY; HUMANS; MICROBIAL SENSITIVITY TESTS; NITROFURANTOIN; RETROSPECTIVE STUDIES; TRIMETHOPRIM; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 62949148863     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00856-08     Document Type: Article

References (28)

1. Bartoloni, A., F. Bartalesi, A. Mantella, E. DeH'Amico, M. Roselli, M. Strohmeyer, H. G. Barahona, V. P. Barron, F. Paradisi, and G. M. Rossolini. 2004. High prevalence of acquired antimicrobial resistance unrelated to heavy antimicrobial consumption. J. Infect. Dis. 189:1291-1294.
2. Bergman, M., S. Huikko, P. Huovinen, P. Paakkari, and H. Seppala. 2006. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae, Antimicrob. Agents Chemother. 50:3646-3650.
3. Bergman, M., S. Huikko, M. Pihlajamaki, P. Laippala, E. Palva, P. Huovinen, and H. Seppala. 2004. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clin. Infect. Dis. 38:1251-1256.
4. Colgan, R., J. R. Johnson, M. Kuskowski, and K. Gupta. 2008. Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis. Antimicrob. Agents Chemother. 52:846-851.
5. Enne, V. L, D. M. Livermore, P. Stephens, and L. M. Hall. 2001. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357:1325-1328.
6. European Antimicrobial Resistance Surveillance System. 2006. EARSS annual report. European Antimicrobial Resistance Surveillance System, Bilthoven, The Netherlands, http://www.rivm.nl/earss/.
7. Farra, A., G. Skoog, L. Wallen, G. Kahlmeter, G. Kronvall, and M. Sorberg. 2002. Antibiotic use and Escherichia coli resistance trends for quinolones and cotrimoxazole in Sweden. Scand. J. Infect. Dis. 34:449-455.
8. Goettsch, W., W. van Pelt, N. Nagelkerke, M. G. Hendrix, A. G. Suiting, P. L. Petit, L, J. Sabbe, A. J. van Griethuysen, and A. J. de Neeling. 2000. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in The Netherlands. J. Antimicrob. Chemother. 46:223-228.
9. Hay, A. D., M. Thomas, A. Montgomery, M. Wetherell, A. Lovering, C. McNulty, D. Lewis, B. Carron, E. Henderson, and A. MacGowan. 2005. The relationship between primary care antibiotic prescribing and bacterial resistance in adults in the community: a controlled observational study using individual patient data. J. Antimicrob. Chemother. 56:146-153.
10. Huovinen, P., L. Sundstrom, G. Swedberg, and O. Skold. 1995. Trimethoprim and sulfonamide resistance. Antimicrob. Agents Chemother. 39:279-289.
11. Kahlmeter, G., P. Menday, and O. Cars. 2003. Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. J. Antimicrob. Chemother. 52:1005-1010.
12. Kärpänoja, P., S. T. Nyberg, M. Bergman, T. Voipio, P. Paakkari, P. Huovinen, and H. Sarkkinen. 2008. Connection between trimethoprim-sulfamethoxazole use and resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 52:2480-2485.
13. Livermore, D. M., D. James, M. Reacher, C. Graham, T. Nichols, P. Stephens, A. P. Johnson, and R. C. George. 2002. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterohacteriaceae from bacteremias, England and Wales. 1990-1999. Emerg. Infect. Dis. 8:473-478.
14. Livermore, D. M., P. Stephens, J. Weinberg, A. P. Johnson, T. Gifford, D. Northcott, D. James, R. C. George, and D. C. Speller. 2000. Regional variation in ampicillin and trimethoprim resistance in Escherichia coli in England from 1990 to 1997, in relation to antibacterial prescribing. J. Antimicrob. Chemother. 46:411-22.
15. MacDougall, C., J. P. Powell, C. K. Johnson, M. B. Edmond, and R. E. Polk. 2005. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin. Infect. Dis. 41:435-440.
16. Manges, A R., J. R. Johnson, B. Foxman, T. T. O'Bryan, K. E. Fullerton, and L. W. Riley. 2001. Widespread distribution of urinary tract infections caused by a multi-drug-resistant Escherichia coli clonal group. N. Engl. J. Med. 345:1007-1013.
17. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disc susceptibility tests. 6th ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
18. Nissinen, A., and P. Huovinen. 2000. FiRe works-the Finnish Study Group for Antimicrobial Resistance (FiRe). Euro. Surveill. 5:133-135.
19. Pena, C, J. M. Albareda, R. Pallares, M, Pujol, F, Tubau, and J. Ariza. 1995. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob. Agents Chemother. 39:520-524.
20. Poirel, L., L. Villa, A. Bertini, J. D. Pitout, P. Nordmann, and A. Carattoli. 2007. Expanded-spectrum beta-lactamase and plasmid-mediated quinolone resistance. Emerg. Infect. Dis. 13:803-805.
21. Rautakorpi, U. M., T. Klaukka, P. Honkanen, M. Makela, T. Nikkarinen, E. Palva, R. Roine, H. Sarkkinen, and P. Huovinen. 2001. Antibiotic use by indication: a basis for active antibiotic policy in the community. Scand. J. Infect. Dis. 33:920-926.
22. Robicsek, A., G. A. Jacoby, and D. C. Hooper. 2006. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 6:629-640.
23. Rogues, A. M., C. Dumartin, B. Amadeo, A. G. Venier, N. Marty, P. Parneix, and J. P. Gachie. 2007. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect. Control Hosp. Epidemiol. 28:1389-1395.
24. Sandegren, L., A. Lindqvist, G. Kahlmeter, and D. I. Andersson. 2008. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J. Antimicrob. Chemother. 62:495-503.
25. Smith, S. P., A. R. Manges, and L. W. Riley. 2008. Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by Escherichia coli clonal group composition. Clin. Infect. Dis. 46:689-695.
26. Steinke, D. T., R, A. Seaton, G. Phillips, T. M. MacDonald, and P. G. Davey. 1999. Factors associated with trimethoprim-resistant bacteria isolated from urine samples. J. Antimicrob. Chemother. 43:841-843.
27. Verbeke, G., and G, Molenberghs (ed.), 1997. Linear mixed models in practice: a SAS-oriented approach. Springe r-Verlag, New York, NY.
28. Working group set up by the Finnish Medical Society Duodecim, the Finnish Society of Nephrology, and the Finnish Association for General Practice. Updated November 2006. Urinary tract infections. Current care guidelines. wwrw.kaypahoito.fi. (In Finnish.)